Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.

Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Winters bring warm drinks and cosy layers, however, for those battling eczema, the winter season may not be pleasant. The ...

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.

Published results showed “Latine” patients with psoriasis in the U.S. have unique experiences with their disease and ...

People can also successfully reduce eczema symptoms using home remedies. People with eczema ... Eczema Association suggests that those with atopic dermatitis should avoid products containing ...

Medically reviewed by William Truswell, MD Dandruff is a mild form of seborrheic dermatitis caused by an overgrowth of the yeast (fungus) Malassezia. It causes oiliness, dryness, white or yellow ...